CATEGORY

Pulmonary arterial hypertension (PAH) is a rare condition with an estimated 146,000 sufferers across the United States, Europe and Japan, yet is estimated that up to 75 per cent of these patients are not recognized and treated. However, in recent years there has been significant investment in developing new therapies, and treatment for this previously neglected disease is set to enter a new era.This new work draws on the recent published literature and reports on clinical trials, to review the latest developments in our understanding of the disease, new advances in therapy and current opinion on best practice approaches to management. Internationally-recognised authorities on PAH provide expert analysis of these advances and critical commentary on the data presented and the implications of these findings for future clinical practice. This book covers primary research and future developments in addition to current practice and the latest trials; offers evidence-based solutions by experts; and, presents a comprehensive review of current treatment options in this complex field.